BK 1701
Alternative Names: BK-1701Latest Information Update: 15 Sep 2022
At a glance
- Originator Bukwang Pharmaceutical
- Developer Bukwang Pharmaceutical; Melior Pharmaceuticals, Inc.
- Class Antihyperglycaemics; Obesity therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Diabetes mellitus; Obesity
Most Recent Events
- 12 Sep 2022 BK 1701 is available for licensing as of 12 Sep 2022 (Bukwang Pharmaceuticals website, September 2022)
- 12 Sep 2022 Early research in Obesity in South Korea (unspecified route) before September 2022 (Bukwang Pharmaceuticals website, September 2022)
- 12 Sep 2022 Early research in Diabetes mellitus in South Korea (unspecified route) (Bukwang Pharmaceuticals website, September 2022)